Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Desmosine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Desmosine. Displaying page 1 of 1.
    EudraCT Number: 2016-000354-35 Sponsor Protocol Number: 2016-01 Start Date*: 2016-05-12
    Sponsor Name:Aarhus University Hospital
    Full Title: High dose antioxidant treatment of patients with cystic fibrosis evaluated by measuring desmosine/isodesmosine in urine
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068288 Cystic fibrosis pulmonary exacerbation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001309-95 Sponsor Protocol Number: MPH966-2-01 Start Date*: 2018-11-30
    Sponsor Name:Mereo BioPharma 4 Ltd
    Full Title: A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 wee...
    Medical condition: Alpha-1 antitrypsin deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DK (Completed) ES (Ongoing) PL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004699-34 Sponsor Protocol Number: D4260C00008 Start Date*: 2008-10-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000753-35 Sponsor Protocol Number: D0520C00010 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Bronchiectasis
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006445 Bronchiectasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000434-34 Sponsor Protocol Number: UMCU-VASC-CO-003 Start Date*: 2023-04-12
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization.
    Medical condition: Pseudoxanthoma elasticum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001530-27 Sponsor Protocol Number: D0520C00009 Start Date*: 2009-03-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002151-25 Sponsor Protocol Number: D4260C00007 Start Date*: 2008-07-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Ta...
    Medical condition: Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000602-30 Sponsor Protocol Number: Kamada-AATInhaled-008 Start Date*: 2019-09-30
    Sponsor Name:Kamada Ltd.
    Full Title: A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha...
    Medical condition: Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) IE (Ongoing) SE (Ongoing) FI (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020763-20 Sponsor Protocol Number: 10072DMcA-CS Start Date*: 2010-10-04
    Sponsor Name:National University of Ireland, Galway
    Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2)
    Medical condition: Acute lung injury
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA